Panacea Biotec Limited has informed the Exchange about Product launch of India s first 100% toxin-free and safe NikoMom Baby Skin Care Products, and Staart Prime Infant Milk Substitute Product by Company s wholly-owned subsidiary, Panacea Biotec Pharma Limited
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
On September 24, 2025, Panacea Biotec's wholly-owned subsidiary Panacea Biotec Pharma Limited (PBPL) launched two new product lines in the Indian domestic market. The first is a range of four baby skin care products — Baby Massage Oil, Baby Head to Toe Wash, Baby Daily Lotion, and Diaper Rash Cream — under the existing 'NikoMom' brand, marketed as India's first 100% toxin-free and safe range free from parabens, sulfates, silicones, mineral oils, and artificial dyes. The second is 'Staart Prime,' an Infant Milk Substitute (IMS) available in Stage 1 and Stages 2-3-4 variants. Both product lines are currently focused on the domestic market, with international launch planned for a later date. The NikoMom skin care range complements the company's existing NikoMom Tape Diapers and Diaper Pants, and all products will be sold via 7NShop.com and online platforms like Amazon, Flipkart, and Tata 1mg.
This is a brand and product portfolio expansion in the consumer healthcare segment, which could help diversify revenue beyond the company's core vaccines and pharmaceuticals business. However, no revenue guidance or financial figures were disclosed, so near-term impact on the stock is likely to be limited to sentiment rather than fundamentals.